When people first hear the term glomerular hyperfiltration (GHF), many assume, “Isn’t a high filtration rate a sign that the kidneys are working well?” While it might sound like a good thing, GHF actually reflects… Glomerular Hyperfiltration May Not Indicate Normal Kidney Function
Recently, SGLT2 inhibitors (SGLT2i) have been proven to provide cardiovascular and renal protection for patients with chronic kidney disease (CKD), effectively slowing renal function decline and reducing proteinuria and blood pressure, regardless of diabetes status.… Effects and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients: Insights from the GREAT-ASTRE Study
🔸 Summary of Key Goals Blood Sugar Control: HbA1c 6.5–7.0%, Fasting Blood Glucose 80–130 mg/dL Blood Pressure Control: Below 130/80 mmHg Proteinuria Reduction: UACR <30 mg/g, at least 50% reduction if present Dyslipidemia Management: LDL… Diabetes and Kidney Disease: Why Do They Occur Together and How to Manage Them Effectively?
Introduction Sodium-glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as crucial pharmacological agents in managing type 2 diabetes, chronic kidney disease (CKD), and cardiovascular disease (CVD). These drug classes provide… Comprehensive Review of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Monotherapy vs. Combination Therapy in CKD and Cardiovascular Disease
Lupus nephritis (LN) is one of the most severe complications of systemic lupus erythematosus (SLE), affecting approximately 35–60% of patients. It can cause significant damage to kidney function, leading to chronic kidney disease (CKD) or… Lupus Nephritis: A New Approach to Treatment Goals – From Clinical to Immunologic Remission
What We Know vs. What We Do: The Kidney Health Paradox 🚨 CKD treatment gap, More than 850 million people worldwide suffer from chronic kidney disease (CKD), which, if left untreated, leads to kidney failure… Bridging CKD treatment gap : Real Solutions
Impact of GLP-1 receptor agonists on cardiac structure and skeletal muscle, Recent studies have shown that GLP-1 receptor agonists (GLP-1 RA) not only help in managing diabetes but also have a positive impact on heart failure… Impact of GLP-1 receptor agonists on cardiac structure and skeletal muscle
SGLT2 inhibitors, Managing Type 2 Diabetes (T2D) often requires selecting medications that balance effectiveness with safety. Sodium-glucose cotransporter-2 (SGLT2) inhibitors are widely used for their ability to lower blood sugar, promote weight loss, and improve… SGLT2 Inhibitors: Balancing Benefits and Risks